Technology Bundle ID: TAB-2770

Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis

Request More Info
Licensing Contact:
Primary Inventors: 
Eric Marston (CDC)
Co-Inventors: 
Edwin Ades (CDC), George Carlone (CDC), Jacquelyn Sampson (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 

In vitro data available

Institute or Center: 
CDC

CDC researchers have isolated select Chlamydophila pneumoniae peptide epitopes for development of vaccines and diagnostic assays. Currently, C. pneumoniae infection of humans has been linked to a wide variety of acute and chronic diseases, such as asthma, endocarditis, atherosclerotic vascular disease, chronic obstructive pulmonary disease, sarcoidosis, reactive arthritis and multiple sclerosis. There is presently no available peptide vaccine for the pathogen and reliable and accurate diagnostic methods are limited.

This technology encompasses polypeptide sequences that are specifically recognized by anti-C. pneumoniae antibodies. These antigens may be useful for improving diagnostic methods by reducing the variability and high backgrounds found with methods that rely on whole organisms for detection. Further, this technology may also be useful for production of peptide or DNA-based vaccines directed against C. pneumoniae.

Applications:
  • C. pneumoniae vaccine and/or therapeutic developments
  • Public health surveillance programs
  • Clinical serological diagnostics development
Advantages:
  • No peptide vaccine for C. pneumoniae is presently available
  • Present assays for the diagnosis of C. pneumoniae infections are laborious and limited in efficacy

Patents

PCT Application PCT/US2002/017278
Filed on 2002-05-31
US Application 60/296,496
Filed on 2001-06-05
US Pat 7,223,836

Issued 2007-05-29

Publications

Marston EL, et al.
PMID 11874892

Updated

Feb 7, 2014

Data Source: 
tts